The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells
Authors:
- 1 June 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (2) , 341-346
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- LXR Activation Reduces Proinflammatory Cytokine Expression in Human CD4-Positive LymphocytesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivityThe Prostate, 2005
- Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid ArteriesCirculation Research, 2004
- Androgenic Suppression of ATP-binding Cassette Transporter A1 Expression in LNCaP Human Prostate Cancer CellsCancer Research, 2004
- Antiproliferative Effect of Liver X Receptor Agonists on LNCaP Human Prostate Cancer CellsCancer Research, 2004
- The androgen receptor: a potential target for therapy of prostate cancerSteroids, 2004
- An oxysterol signalling pathway mediated by the nuclear receptor LXRαNature, 1996
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990
- DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled waterAnalytical Biochemistry, 1990
- The use of a hydroxylapatite-filter steroid receptor assay method in the study of the modulation of androgen receptor interactionJournal of Steroid Biochemistry, 1984